Current Problems in Cardiology
Volume 32, Issue 9 , Pages 501-546 , September 2007

Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapy

References 

  1. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44:1268–1275
  2. Nabel EG. Cardiovascular disease. N Engl J Med. 2003;349:60–72
  3. Seidl K, Senges J. Worldwide utilization of implantable cardioverter/defibrillators now and in the future. Card Electrophysiol Rev. 2003;7:5–13
  4. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334–2351
  5. Kannel WB, Thomas HE. Sudden coronary death: the Framingham Study. Ann NY Acad Sci. 1982;382:3–21
  6. State-specific mortality from sudden cardiac death—United States, 1999. MMWR Morb Mortal Wkly Rep. 2002;51:123–126
  7. Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158–2163
  8. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death (Structure, function, and time-dependence of risk). Circulation. 1992;85:I2–I10
  9. Myerburg RJ, Mitrani R, Interian A, et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97:1514–1521
  10. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482
  11. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996;334:1039–1044
  12. Valdes-Dapena M. Are some crib deaths sudden cardiac deaths?. J Am Coll Cardiol. 1985;5:113B–117B
  13. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes (Clinical, demographic, and pathological profiles). JAMA. 1996;276:199–204
  14. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res. 2001;50:399–408
  15. Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation. 2000;102:649–654
  16. Mehta D, Curwin J, Gomes JA, et al. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation. 1997;96:3215–3223
  17. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–1680
  18. Pratt CM, Greenway PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death (Implications for the interpretation of clinical trials). Circulation. 1996;93:519–524
  19. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117:151–159
  20. Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39:1323–1328
  21. Kuo CS, Munakata K, Reddy CP, et al. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation. 1983;67:1356–1367
  22. Mandapati R, Asano Y, Baxter WT, et al. Quantification of effects of global ischemia on dynamics of ventricular fibrillation in isolated rabbit heart. Circulation. 1998;98:1688–1696
  23. Kuo CS, Amlie JP, Munakata K, et al. Dispersion of monophasic action potential durations and activation times during atrial pacing, ventricular pacing, and ventricular premature stimulation in canine ventricles. Cardiovasc Res. 1983;17:152–161
  24. Ht Everett T, Wilson EE, Foreman S, et al. Mechanisms of ventricular fibrillation in canine models of congestive heart failure and ischemia assessed by in vivo noncontact mapping. Circulation. 2005;112:1532–1541
  25. Link MS, Estes NA. Mechanically induced ventricular fibrillation (commotio cordis). Heart Rhythm. 2007;4:529–532
  26. Fitzsimmons PJ, McWhirter PD, Peterson DW, et al. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. Am Heart J. 2001;142:530–536
  27. Leitch JW, Klein GJ, Yee R, et al. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation. 1990;82:1718–1723
  28. Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation. 1993;87:866–873
  29. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol. 2003;41:239–244
  30. Pappone C, Manguso F, Santinelli R, et al. Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N Engl J Med. 2004;351:1197–1205
  31. Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes (The GUSTO Investigators). Circulation. 1998;98:2567–2573
  32. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002;106:309–312
  33. Gheeraert PJ, Henriques JP, De Buyzere ML, et al. Out-of-hospital ventricular fibrillation in patients with acute myocardial infarction: coronary angiographic determinants. J Am Coll Cardiol. 2000;35:144–150
  34. Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction (Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study). JAMA. 1992;268:1545–1551
  35. Nazarian S, Bluemke D, Lardo A, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821–2825
  36. Kannel WB, Wilson PW, D’Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998;136:205–212
  37. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611–616
  38. Gardin J, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001;87:1051–1057
  39. Burke AP, Farb A, Liang YH, et al. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation. 1996;94:3138–3145
  40. Spirito P, Bellone P, Harris K, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778–1785
  41. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145–2161
  42. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–2164
  43. Moon J, McKenna W, McCrohon J, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1567
  44. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–2218
  45. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:974–980
  46. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991;68:1388–1392
  47. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046–1051
  48. Dubrey SW, Bilazarian S, LaValley M, et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134:994–1001
  49. Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001;38:1773–1781
  50. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005;112:3823–3832
  51. Corrado D, Basso C, Schiavon M, et al. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339:364–369
  52. Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry (Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation). Circulation. 2000;101:E101–E106
  53. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy (Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology). Br Heart J. 1994;71:215–218
  54. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–1372
  55. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022
  56. Roden DM. Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029–1034
  57. Vincent GM. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med. 1998;49:263–274
  58. Schwartz PJ. The long QT syndrome. Curr Probl Cardiol. 1997;22:297–351
  59. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes (KVLQT1, HERG, SCN5A, KCNE1, and KCNE2). Circulation. 2000;102:1178–1185
  60. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421:634–639
  61. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95
  62. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001;22:1374–1450
  63. Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation. 2003;108:965–970
  64. Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003;14:1273–1277
  65. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43:1494–1499
  66. Osher HL, Wolff L. Electrocardiographic pattern simulating acute myocardial injury. Am J Med Sci. 1953;226:541–545
  67. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome (A multicenter report). J Am Coll Cardiol. 1992;20:1391–1396
  68. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997;96:2595–2600
  69. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–296
  70. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–515
  71. Rolf S, Bruns HJ, Wichter T, et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J. 2003;24:1104–1112
  72. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003;108:3092–3096
  73. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–1347
  74. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731–1737
  75. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–1666
  76. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97:457–460
  77. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659–670
  78. Francis J, Sankar V, Nair VK, et al. Catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2005;2:550–554
  79. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children (A 7-year follow-up of 21 patients). Circulation. 1995;91:1512–1519
  80. Laitinen PJ, Swan H, Kontula K. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet. 2003;11:888–891
  81. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA. 2004;101:9137–9142
  82. Hasdemir C, Priori SG, Overholt E, et al. Catecholaminergic polymorphic ventricular tachycardia, recurrent syncope, and implantable loop recorder. J Cardiovasc Electrophysiol. 2004;15:729
  83. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89:66–70
  84. Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J. 1990;120:661–671
  85. Saumarez RC, Chojnowska L, Derksen R, et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation. 2003;107:2595–2600
  86. Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol. 1993;21:1406–1412
  87. Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106:962–967
  88. Morrison LJ, Dorian P, Long J, et al. Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). Resuscitation. 2005;66:149–157
  89. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med. 1990;19:179–186
  90. Buxton A, Lee K, Fisher J, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease (Multicenter Unsustained Tachycardia Trial Investigators). N Engl J Med. 1999;341:1882–1890
  91. Wood M, Stambler B, Ellenbogen K. Recent insights in programmed electrical stimulation for the management of sustained ventricular arrhythmias. Curr Opin Cardiol. 1994;9:3–11
  92. Andresen D, Steinbeck G, Bruggemann T, et al. Risk stratification following myocardial infarction in the thrombolytic era: a two-step strategy using noninvasive and invasive methods. J Am Coll Cardiol. 1999;33:131–138
  93. Kendall MJ, Lynch KP, Hjalmarson A, et al. Beta-blockers and sudden cardiac death. Ann Intern Med. 1995;123:358–367
  94. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  95. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–807
  96. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1704–1714
  97. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction (A double-blind randomised trial). Lancet. 1981;2:823–827
  98. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13:28–32
  99. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–1632
  100. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  101. Lerman BB, Engelstein ED, Burkhoff D. Mechanoelectrical feedback: role of beta-adrenergic receptor activation in mediating load-dependent shortening of ventricular action potential and refractoriness. Circulation. 2001;104:486–490
  102. Crijns HJ, Wiesfeld AC, Posma JL, et al. Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias. Br Heart J. 1995;74:408–412
  103. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction (The Cardiac Arrhythmia Suppression Trial II Investigators). N Engl J Med. 1992;327:227–233
  104. The cardiac arrhythmia suppression trial. N Engl J Med. 1989;321:1754–1756
  105. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators). Lancet. 1997;349:675–682
  106. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT (European Myocardial Infarct Amiodarone Trial Investigators). Lancet. 1997;349:667–674
  107. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  108. De Sutter J, De Bacquer D, Jordaens L. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators. Boston, MA: Heart Rhythm Society Scientific Sessions; 2006;
  109. Leaf A, Xiao YF, Kang JX, et al. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Membr Biol. 2005;206:129–139
  110. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762–2768
  111. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884–2891
  112. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol. 1989;13:1353–1361
  113. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias (The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators). N Engl J Med. 1997;337:1576–1583
  114. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–754
  115. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–1302
  116. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia (Multicenter Automatic Defibrillator Implantation Trial Investigators). N Engl J Med. 1996;335:1933–1940
  117. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  118. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease (Multicenter Unsustained Tachycardia Trial Investigators). N Engl J Med. 1999;341:1882–1890
  119. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery (Coronary Artery Bypass Graft (CABG) Patch Trial Investigators). N Engl J Med. 1997;337:1569–1575
  120. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  121. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–2588
  122. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453–1458
  123. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol. 2003;41:1707–1712
  124. Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation. 2006;113:776–782
  125. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol. 2000;85:981–985
  126. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–2879
  127. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med. 2003;138:445–452
  128. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol. 2003;41:1573–1582
  129. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247–e346
  130. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  131. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549
  132. Higgins SL. Impact of the Multicenter Automatic Defibrillator Implantation Trial on implantable cardioverter defibrillator indication trends. Am J Cardiol. 1999;83:79D–82D
  133. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med. 2005;352:222–224
  134. Morgan JM. Cost-effectiveness of implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2002;13:S114–S117
  135. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885–1889
  136. Anvari A, Stix G, Grabenwoger M, et al. Comparison of three cardioverter defibrillator implantation techniques: initial results with transvenous pectoral implantation. Pacing Clin Electrophysiol. 1996;19:1061–1069
  137. Cardinal DS, Connelly DT, Steinhaus DM, et al. Cost savings with nonthoracotomy implantable cardioverter-defibrillators. Am J Cardiol. 1996;78:1255–1259
  138. Godemann F, Butter C, Lampe F, et al. Panic disorders and agoraphobia: side effects of treatment with an implantable cardioverter/defibrillator. Clin Cardiol. 2004;27:321–326
  139. Fromer M, Brachmann J, Block M, et al. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator (Results of a European multicenter study of 102 implants). Circulation. 1992;86:363–374
  140. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104:796–801
  141. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591–2596
  142. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589–594
  143. Singh JP, Hall WJ, McNitt S, et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol. 2005;46:1712–1720
  144. Stecker E, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47:1161–1166
  145. Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2006;47:1820–1827
  146. Gehi AK, Stein RH, Metz LD, et al. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol. 2005;46:75–82
  147. Armoundas AA, Hohnloser SH, Ikeda T, et al. Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation?. Nat Clin Pract Cardiovasc Med. 2005;2:522–528
  148. Costantini O. The Alternans Before Cardioverter Defibrillator (ABCD) trial: A non-invasive strategy for primary prevention of sudden cardiac death using T wave alternans. American Heart Association 2006 Scientific Sessions; November 15, 2006. Late Breaking Clinical Trials III.
  149. Bloomfield DM, Bigger JT, Steinmac RC, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006;47:456–463
  150. Ikeda T, Yoshino H, Sugi K, et al. Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction: results of a collaborative cohort study. J Am Coll Cardiol. 2006;48:2268–2274
  151. Chan PS, Stein K, Chow T, et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48:112–121
  152. Rollins J. NCD for Microvolt T-Wave Alternans (MTWA) (20.30). In: Services DoHH, editor. Center for Medicare and Medicaid Services (CMS), 2005.
  153. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733–2743
  154. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA. 2006;295:1901–1906
  155. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005;6:95–108
  156. Liggett SB. Polymorphisms of adrenergic receptors: variations on a theme. Assay Drug Dev Technol. 2003;1:317–326
  157. McNamara DM, MacGowan GA, London B. Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. Am J Pharmacogenomics. 2002;2:73–78
  158. Sotoodehnia N, Siscovick DS, Vatta M, et al. Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006;113:1842–1848
  159. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526–1533
  160. Burke A, Creighton W, Mont E, et al. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation. 2005;112:798–802
  161. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation. 2006;113:338–344

PII: S0146-2806(07)00068-0

doi: 10.1016/j.cpcardiol.2007.05.002

Current Problems in Cardiology
Volume 32, Issue 9 , Pages 501-546 , September 2007

Article Tools

* Image Usage & Resolution